<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918303</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2020/55</org_study_id>
    <nct_id>NCT04918303</nct_id>
  </id_info>
  <brief_title>Skin Sympathetic Nerve Activity and Cardiac Arrhythmia</brief_title>
  <acronym>SKNA</acronym>
  <official_title>Skin Sympathetic Nerve Activity and Cardiac Arrhythmia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sympathetic tone is important in cardiac arrhythmogenesis. The simultaneous recording of&#xD;
      sympathetic nerve activity (SNA) and electrocardiogram (ECG) was obtained by invasive method.&#xD;
      The purpose of this protocol is to further develop this recording method to turn it into a&#xD;
      new non-invasive tool for arrhythmia prediction and detection. This method may also be useful&#xD;
      in validating the results of surgical procedures aimed at sympathetic denervation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2021</start_date>
  <completion_date type="Anticipated">November 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 3, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delay between the discharge of the sympathetic system and the rhythmic event.</measure>
    <time_frame>Day 1</time_frame>
    <description>Temporal correlation of occurrence of sympathetic electrical event and cardiac arrhythmia by the MacNemar test will be performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Delay between the discharge of the sympathetic system and the rhythmic event.</measure>
    <time_frame>Day 2</time_frame>
    <description>Temporal correlation of occurrence of sympathetic electrical event and cardiac arrhythmia by the MacNemar test will be performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Delay between the discharge of the sympathetic system and the rhythmic event.</measure>
    <time_frame>Month 6</time_frame>
    <description>Temporal correlation of occurrence of sympathetic electrical event and cardiac arrhythmia by the MacNemar test will be performed.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sudden Death</condition>
  <condition>Ventricular Tachycardia</condition>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>SKNA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SKNA recording</intervention_name>
    <description>The coupled recording of the sympathetic nervous activity of the skin and of an ECG will be carried out using the ME6000 device, CE marked, from the Bittium company.&#xD;
It will be performed for a maximum period of one hour at Day 1, Post-procedure between Day 1 and discharge from hospital, and month 6</description>
    <arm_group_label>SKNA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - patient hospitalized at Bordeaux University Hospital for sudden death, ventricular&#xD;
        tachycardia, persistent or paroxysmal atrial fibrillation treated by ablation and/or vein&#xD;
        of Marshall ethanol infusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy,&#xD;
&#xD;
          -  patient under 18 year old,&#xD;
&#xD;
          -  patient with a cardiac stimulation device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mélèze Hocini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mélèze Hocini, MD</last_name>
    <phone>(0)5 57 63 34 06</phone>
    <phone_ext>+33</phone_ext>
    <email>meleze.hocini@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maëlle Vallade</last_name>
    <phone>(0)5 24 54 92 58</phone>
    <phone_ext>+33</phone_ext>
    <email>maelle.vallade@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mélèze Hocini, MD</last_name>
      <phone>(0)5 57 63 34 06</phone>
      <phone_ext>+33</phone_ext>
      <email>meleze.hocini@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Maëlle Vallade</last_name>
      <phone>(0)5 24 54 92 58</phone>
      <phone_ext>+33</phone_ext>
      <email>maelle.vallade@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Mélèze Hocini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin sympathetic nerve activity (SKNA)</keyword>
  <keyword>Electrocardiogram (ECG)</keyword>
  <keyword>Cardiac arrythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Death, Sudden</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

